The Ledger

5.7 billion dollars: that is what KKR is paying to take the world’s largest pure-play medical device contract manufacturer private, a 52 percent premium and the biggest healthcare buyout of the week. Integer Holdings Corporation, which makes components for pacemakers, neurostimulators and cardiac rhythm devices under the Greatbatch Medical and Lake Region Medical brands and employs roughly 11,000 people, agreed August 3, 2026 to be acquired by KKR for 127 dollars a share in cash, an enterprise value of approximately 5.7 billion dollars. The price is a 51.8 percent premium to Integer’s closing price on April 29, 2026, the day before it announced a strategic review, and a 28.8 percent premium to its 30 day volume weighted average price through July 31. The deal carries no financing contingency, funded through KKR’s own equity plus committed debt, and is expected to close by year end 2026 subject to shareholder and regulatory approval; KKR says it will set up a broad based employee ownership program after closing. Confidence: High. The price, premium calculations and financing terms come directly from the companies’ own announcement and Integer’s SEC filing. Sources: Integer to Be Acquired by KKR in Transaction Valued at Approximately $5.7 Billion, GlobeNewswire, Integer Holdings Corporation Form 8-K exhibit, U.S. Securities and Exchange Commission.

8 billion dollars, 2.1 billion of it: that is the new money Medicare is putting into hospital payments next year, tied to a rule that also makes a joint replacement bundled payment mandatory nationwide for the first time. The Centers for Medicare and Medicaid Services finalized its fiscal year 2027 Hospital Inpatient Prospective Payment System rule this week, setting a 2.3 percent net payment rate increase that CMS projects will raise aggregate hospital payments by approximately 2.1 billion dollars, plus another 779 million dollars in new technology add on payments. The same rule expands the Comprehensive Care for Joint Replacement model into “CJR-X,” requiring every eligible hospital nationwide, not a voluntary subset, to take on bundled financial risk for hip, knee and ankle replacement episodes performed in inpatient and hospital outpatient settings; the mandatory start date was pushed back to January 1, 2028, giving hospitals and the device makers that supply them, Stryker, Zimmer Biomet and Johnson & Johnson MedTech among them, roughly 17 months to prepare for a first of its kind nationwide bundle. Confidence: High. The payment figures and CJR-X mandate come directly from the rule itself in the Federal Register and CMS’s own announcement. Sources: FY 2027 Hospital Inpatient Prospective Payment System final rule (CMS-1849-F), Federal Register, CMS Announces Nationwide Expansion of Proven Joint Replacement Program, Centers for Medicare and Medicaid Services; per reporting by CMS locks in 2.3% IPPS increase, bumps back start of CJR-X Model, Fierce Healthcare.

15 billion dollars: that is Pfizer’s second quarter revenue, beating Wall Street by more than half a billion dollars, as the company raised its full year outlook for the second time this year. Pfizer reported second quarter 2026 revenue of 15.03 billion dollars, up 3 percent, ahead of the roughly 14.45 billion dollar consensus estimate, with adjusted diluted earnings per share of 0.77 dollars beating the 0.68 dollar estimate; excluding Comirnaty and Paxlovid, revenue grew 5 percent operationally and revenue from launched and acquired products rose 18 percent operationally, offsetting a continued decline in the COVID-19 portfolio. Pfizer raised its full year 2026 revenue guidance by 500 million dollars at the midpoint to a range of 60.5 billion to 62.5 billion dollars, while reaffirming adjusted earnings per share guidance, which absorbs a roughly 0.10 dollar hit tied to its Innovent Biologics transaction. Confidence: High, since the reported and guidance figures come directly from the company’s own release. Source: Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance, Business Wire.

5.89 billion dollars: that is the size of the US market a new interchangeable biosimilar just entered, aimed straight at Regeneron’s best selling eye drug. Biocon launched Yesafili, an FDA interchangeable biosimilar to Regeneron’s Eylea 2 mg, in the United States on August 3, 2026, cleared for wet age related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; Biocon’s own announcement cites approximately 19.8 million Americans living with age related macular degeneration and puts total US aflibercept sales at roughly 5.89 billion dollars in 2023, the market Yesafili is now designed to take share from through pharmacy level substitution the interchangeable designation allows. Confidence: High, since the launch, indication and interchangeability status come directly from Biocon’s own release. Source: Biocon Announces U.S. Commercial Launch of Yesafili, a Biosimilar to Regeneron’s EYLEA 2 mg, Biocon.

139 positions: that is how many jobs a major nonprofit hospital system is cutting across two California hospitals, even as it markets itself as mid-turnaround. Dignity Health, part of CommonSpirit Health, confirmed 57 permanent layoffs at Bakersfield Memorial Hospital effective August 3, 2026, including 33 registered nurses plus a nurse educator, safety nurse, emergency department licensed vocational nurse, transcriptionist, orderly and unit secretary, alongside a companion notice of 82 proposed layoffs at California Hospital Medical Center in Los Angeles that includes the entire pediatric unit nursing staff, for 139 positions total. Dignity Health attributed the cuts to “realigning resources and enhancing operational efficiencies”; the layoffs follow the June 30 closure of Kern County’s only burn center and come as CommonSpirit works through a multiyear turnaround after reporting more than 1 billion dollars in operating losses over the first nine months of a recent fiscal year. Confidence: Medium. Multiple independent local and trade outlets and a nursing union corroborate the same figures and cite state Worker Adjustment and Retraining Notification filings, but this run could not independently retrieve the underlying WARN notice itself. Sources: Dignity Health to layoff 139 workers across 2 California hospitals, Becker’s Hospital Review, Memorial Hospital to lay off 57 workers in August, Dignity Health confirms, KGET/turnto23.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Integer Holdings Corporation	KKR	Medtech, contract device manufacturing (CDMO)	$127/share cash, approximately $5.7 billion enterprise value; no financing contingency, expected close by year end 2026	Integer to Be Acquired by KKR, GlobeNewswire
Catalyst Healthcare Real Estate development pipeline	Nuveen Real Estate (joint venture)	Healthcare real estate, medical office and specialty facility development	$400 million equity joint venture funding approximately $1.3 billion of new developments through 2028	Catalyst Healthcare Real Estate and Nuveen Real Estate Announce $400 Million Equity Joint Venture, PR Newswire

CVS Health, agilon health and Clover Health report second quarter results Wednesday, August 5; Privia Health and Oscar Health follow Thursday, August 6; Amgen, Novo Nordisk and Eli Lilly are also on this week’s earnings calendar.